Navigation Links
AMIA advises FDA on clinical decision support
Date:9/14/2011

Washington, DCIn response to the U.S. Food and Drug Administration's (FDA) invitation to participate in a public workshop related to FDA's Draft Guidance on mobile medical applications, AMIAthe association for informatics professionalsadvised the FDA on how it should approach oversight of clinical decision support systems. The critical factor, stated AMIA, in determining the risk classification of different types of software that provide clinical decision support (CDS) is whether the CDS is mediated by a human being or not. The FDA's most rigorous attention, AMIA pointed out, should be given to applications that provide CDS in an automatic and autonomous fashion, and which intervene directly, based on patient care data. AMIA's comments were delivered by Meryl Bloomrosen, Vice President for Public Policy and Government Relations.

AMIA cautioned the FDA about the future blurring of lines between CDS information delivery channels and mechanisms, devices, and applications intended primarily for use by clinicians and other providers, contrasted with those intended for patients, consumers and their care-givers. AMIA also questioned the singling out of "stand-alone" CDS delivered via "mobile medical devices" as being suitable for FDA oversight, more than other kinds of clinical software environments, such as desktop computers.

"AMIA's comments are premised upon practical evidence that the health sector is exploding with an array of clinical information systems for potential use in a broad range of settings," said AMIA President and CEO Edward H. Shortliffe, MD, PhD, FACMI. "A growing volume of research demonstrates that health information technology in many forms and on many kinds of devices can improve the quality and safety of patient care, and promote efficiencies in overall care delivery. In this modern era of ubiquitous electronic data and access, it is important to have regulations that keep pace with cliniciansmany of whom are becoming quite expert at using technology to access pertinent information, and thereby streamlining healthcare delivery and improving overall health."

The Sept. 12-13 workshop fostered discussion between FDA officials and interested stakeholders about the FDA's proposed oversight approach to mobile medical applications. The applications under discussion are those that serve as accessories to other medical devices, that are stand-alone software that provide clinical decision support, and that are for use on smartphones and other mobile computing devices. Prior to the workshop, the FDA had identified a subset of mobile medical applications that might have impact on the performance of currently regulated medical devices, and as such would require FDA oversight.

In its presentation, AMIA focused on several key areas:

  • The need for the FDA to articulate how it characterizes and defines "CDS".
  • The need to coordinate efforts among federal agencies and public- and private-sector research and practice communities.
  • The potential limitations if FDA focuses too narrowly on CDS, and considers CDS on mobile devices as somehow separate from CDS based on other delivery methods or contexts.
  • The importance of addressing rapidly emerging and converging technologies and devices along with new and evolving forms of patient care delivery (such as medical homes and accountable care organizations) and payment methods.


'/>"/>

Contact: Nancy Light
nlight@amia.org
301-657-5903
American Medical Informatics Association
Source:Eurekalert

Related biology news :

1. Overwhelmed by diet tips? Change your environment first, study advises
2. Reports highlight the evolving role of clinical microbiology laboratories
3. New research validates clinical importance of leukemia stem cells
4. Clinical study shows young brains lack the wisdom of their elders
5. Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment
6. Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting
7. New IOF-ISCD review clarifies the use of FRAX in clinical practice
8. New edition of Manual of Clinical Microbiology offers digital access
9. Clinical tests for medicines made from genetically modified plants
10. Omnicare Clinical Research Re-Brands as Theorem Clinical Research
11. NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology: